The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
10,876
Sort by:
High Mobility Group Protein B1 - Drugs In Development, 2021
US$ 3,500.00
High Mobility Group Protein B1 - Drugs In Development, 2021 SUMMARY According to the recently published report 'High Mobility Group Protein B1 - Drugs In Development, 2021'; High Mobility Group Protei...
July 2021
57 pages
Hodgkin Lymphoma (Oncology) - Drugs In Development, 2021
US$ 2,000.00
Hodgkin Lymphoma (Oncology) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma - Drugs In Development, 2021, prov...
July 2021
1353 pages
Leiomyosarcoma (Oncology) - Drugs In Development, 2021
US$ 2,000.00
Leiomyosarcoma (Oncology) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Drugs In Development, 2021, provides...
July 2021
827 pages
Measles (Infectious Disease) - Drugs In Development, 2021
US$ 2,000.00
Measles (Infectious Disease) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Measles - Drugs In Development, 2021, provides an...
July 2021
53 pages
Melanocortin Receptor 4 - Drugs In Development, 2021
US$ 3,500.00
Melanocortin Receptor 4 - Drugs In Development, 2021 SUMMARY Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by...
July 2021
88 pages
Myc Proto Oncogene Protein - Drugs In Development, 2021
US$ 3,500.00
Myc Proto Oncogene Protein - Drugs In Development, 2021 SUMMARY Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes cl...
July 2021
69 pages
Neutropenia (Hematology) - Drugs In Development, 2021
US$ 2,000.00
Neutropenia (Hematology) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Drugs In Development, 2021, provides an...
July 2021
150 pages
Nociceptin Receptor - Drugs In Development, 2021
US$ 3,500.00
Nociceptin Receptor - Drugs In Development, 2021 SUMMARY According to the recently published report 'Nociceptin Receptor - Drugs In Development, 2021'; Nociceptin Receptor (Kappa Type 3 Opioid Recepto...
July 2021
58 pages
Oligodendroglioma (Oncology) - Drugs In Development, 2021
US$ 2,000.00
Oligodendroglioma (Oncology) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Drugs In Development, 2021, pr...
July 2021
201 pages
